ELIGIBLE COMMERCIALLY INSURED PATIENTS PAY AS LITTLE AS $0 PER PRODUCT PER PRESCRIPTION.*
*Prescriptions that may be reimbursed under federal or state healthcare programs (including Medicaid and Medicare) are not eligible under this program. Additional restrictions apply.
Co-Pay Card Savings Program
or send it to your retail pharmacy of choice.
then download or print the card.
to receive the discount.
Why HALOG® Solution?
See Proven ResultsHave questions about HALOG® Solution?
View FAQsINDICATIONS AND USAGE
HALOG® Solution (Halcinonide Topical Solution, USP) 0.1%, HALOG (Halcinonide Cream, USP) 0.1% and HALOG (Halcinonide OINTMENT, USP) 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
PRECAUTIONS
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse Reactions
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information of respective products.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.